NCT06297616CompletedPhase 1
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3841136 Monotherapy, and LY3841136 in Combination With Tirzepatide, in Japanese Participants With Obesity or Overweight
Source: ClinicalTrials.gov · Last updated 16 Jan 2026
Brief summary (registry, in English)
The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 128 (actual)
- First submitted
- 1 Mar 2024
- Start date
- Apr 2024
- Primary completion date
- Nov 2025
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT06297616
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 128
- From Apr 2024 to the primary completion date, Nov 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have had within the last 6 months, or plan to have during the study, a device-based or surgical treatment use for obesity
- Have been treated, or plan to be treated, with prescription medications or other non-approved drugs intended to promote weight loss, within 3 months prior to screening
- For participants in Part B, have previously received tirzepatide within 6 months prior to screening
Other illness
- Have a history of significant atopy (severe allergic manifestations), multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions
- Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, bipolar disorder within the last 3 years
- Have been diagnosed with Type 1 or Type 2 Diabetes Mellitus
- Have a history of chronic medical conditions involving the heart, liver, or kidneys
- Have a history of any malignancy within the past 5 years
- Have a history or presence of a GI disorder
- For participants in Part B, have a personal or family history of medullary thyroid carcinoma, or have multiple endocrine neoplasia syndrome type 2
Who the study is looking for
- Male or female participants who agree to contraception requirements
- Have a body mass index (BMI) within the range of 27 to 40 kg/m², inclusive
- Have had a stable weight for the 3 months
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hakata Clinic Coordinator of this site? Confirm its status | Fukuoka | Japan | Unknown status |
| P-One Clinic Coordinator of this site? Confirm its status | Hachiōji | Japan | Unknown status |
| Sumida Hospital Coordinator of this site? Confirm its status | Sumida-ku | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.